Trevena Begins Clinical Development Of TRV734 - Quick Facts

(RTTNews) - Trevena Inc. (TRVN) announced the initiation of its first Phase 1 trial for TRV734, a novel drug candidate in development as an orally administered treatment for moderate to severe acute and chronic pain.

TRV734 is being developed to optimize analgesia while minimizing on-target gastrointestinal and respiratory effects through its novel biased ligand mechanism at the mu-opioid receptor. TRV734 takes advantage of the same receptor specificity mechanism as does Trevena's Phase 2 clinical candidate, TRV130, an intravenous mu-opioid G protein biased ligand being developed for acute postoperative pain.

"In preclinical studies, TRV734 demonstrated an encouraging therapeutic profile, with a potent analgesic effect and a reduced impact on gastrointestinal motility at equianalgesic doses compared to oxycodone. We look forward to further evaluating its potential in a clinical setting," said David Soergel, senior vice president of clinical development at Trevena.

The company said that the main objective of this first-in-human trial is to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of single ascending doses of TRV734 in healthy subjects. The potentially efficacious dose range of TRV734 will also be evaluated using pupilometry, a validated biomarker for mu-opioid receptor engagement.